Skip to main content

What the FDA labels say about taking them together

Dalfampridine and dolutegravir

Dolutegravir's FDA label of May 22, 2026 names dalfampridine in its drug interactions section; the dalfampridine label PlainMeds reads does not name dolutegravir. The dolutegravir label: “Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1.”

Check it at the source: the dalfampridine FDA label on DailyMed (effective January 16, 2026, Merz Pharmaceuticals, LLC); the dolutegravir FDA label on DailyMed (effective May 22, 2026, ST. MARY'S MEDICAL PARK PHARMACY).

What does the dalfampridine label say about dolutegravir?

Dalfampridine's label (effective January 16, 2026) does not name dolutegravir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (AMPYRA), Merz Pharmaceuticals, LLC, effective January 16, 2026 (SPL set 550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783), via openFDA; the full label on DailyMed

What does the dolutegravir label say about dalfampridine?

Dolutegravir label, drug interactions

Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin, Table 8 ) [see Contraindications ( 4 ), Drug Interactions ( 7.3 )].

Source: FDA drug label (Tivicay), NDA204790 (Viiv Hlthcare), as published by ST. MARY'S MEDICAL PARK PHARMACY, effective May 22, 2026 (SPL set 485bc9db-8665-9f5a-e063-6394a90a7921), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

9Dalfampridine generic labelers
0Dolutegravir generic labelers
DalfampridineDolutegravir
Labeled forMultiple sclerosisHIV
Boxed warningNoNo
Pharmacy cost (NADAC)$0.399 per tablet 10 mg tablet$77.64 per tablet 50 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?